Our top pick for
10x Genomics, Inc is a health information services business based in the US. 10x Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10x Genomics employs 584 staff and has a trailing 12-month revenue of around USD$298.8 million.
|52-week range||USD$48.78 - USD$201.7|
|50-day moving average||USD$177.2415|
|200-day moving average||USD$144.166|
|Wall St. target price||USD$195.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-7.271|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing 10x Genomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of 10x Genomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
10x Genomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$10.1 million.
The EBITDA is a measure of a 10x Genomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$298.8 million|
|Gross profit TTM||USD$240.4 million|
|Return on assets TTM||-6.95%|
|Return on equity TTM||-93.64%|
|Market capitalisation||USD$19 billion|
TTM: trailing 12 months
There are currently 941,229 10x Genomics shares held short by investors – that's known as 10x Genomics's "short interest". This figure is 13.5% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting 10x Genomics shares can be evaluated.
10x Genomics's "short interest ratio" (SIR) is the quantity of 10x Genomics shares currently shorted divided by the average quantity of 10x Genomics shares traded daily (recently around 847954.05405405). 10x Genomics's SIR currently stands at 1.11. In other words for every 100,000 10x Genomics shares traded daily on the market, roughly 1110 shares are currently held short.
However 10x Genomics's short interest can also be evaluated against the total number of 10x Genomics shares, or, against the total number of tradable 10x Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 10x Genomics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 10x Genomics shares in existence, roughly 10 shares are currently held short) or 0.012% of the tradable shares (for every 100,000 tradable 10x Genomics shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against 10x Genomics.
Find out more about how you can short 10x Genomics stock.
We're not expecting 10x Genomics to pay a dividend over the next 12 months.
10x Genomics's shares were split on a 1:2 basis on 17 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10x Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10x Genomics shares which in turn could have impacted 10x Genomics's share price.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.